ストックスクリーナーアプリを入手
31.28
0.06%
-0.02
アフターアワーズ：
31.28
Amphastar Pharmaceuticals Inc (AMPH) 最新ニュース
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Short Interest Update - MarketBeat
Can Amphastar's High-Value Pipeline Strategy Show Results? Q4 Earnings Preview - StockTitan
Amphastar Pharmaceuticals (NASDAQ:AMPH) Reaches New 12-Month LowHere's Why - MarketBeat
Amphastar Pharmaceuticals: A Gradual Strategy (NASDAQ:AMPH) - Seeking Alpha
Amphastar Pharmaceuticals to Present at the Bank of America Securities Health Care Conference - ACCESS Newswire
Amphastar Pharmaceuticals (AMPH) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Dextrose Injection Market: Demand, Growth, and Innovations 2025-2032 | Pfizer Inc., Amphastar Pharmaceuticals Inc - openPR
Yousif Capital Management LLC Lowers Stock Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Defense World
How the (AMPH) price action is used to our Advantage - Stock Traders Daily
State of Alaska Department of Revenue Sells 342 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Defense World
Polaris Capital Management LLC Buys Shares of 24,500 Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - MarketBeat
Unpacking Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) In The Context Of Other Generic Pharmaceuticals Stocks - The Globe and Mail
Amphastar stock hits 52-week low at $31.54 amid market challenges - Investing.com Canada
Amphastar stock hits 52-week low at $34.08 amid market challenges - Investing.com Nigeria
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? - Simply Wall St
Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Gap DownShould You Sell? - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Rating Lowered by Piper Sandler - MarketBeat
Boston Trust Walden Corp Purchases 439,281 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Reaches New 52-Week LowHere's Why - MarketBeat
Piper Sandler Downgrades Amphastar Pharmaceuticals (NASDAQ:AMPH) to Neutral - Defense World
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Sees Large Growth in Short Interest - MarketBeat
Piper Sandler Downgrades Amphastar Pharmaceuticals (AMPH) - MSN
Piper Sandler cuts Amphastar stock rating, slashes price target By Investing.com - Investing.com Canada
Market Resilience: Amphastar Pharmaceuticals Inc (AMPH) Finishes Weak at 33.39, Down -4.24 - The Dwinnex
This Ollie's Bargain Outlet Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Piper Sandler Downgrades Amphastar Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $36 From $66 - Marketscreener.com
Piper Sandler cuts Amphastar stock rating, slashes price target - MSN
Long Term Trading Analysis for (AMPH) - Stock Traders Daily
Amphastar Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference - ACCESS Newswire
BofA Adjusts Price Target on Amphastar Pharmaceuticals to $44 From $46 -February 03, 2025 at 10:16 am EST - Marketscreener.com
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Purchased by Pacer Advisors Inc. - MarketBeat
Amphastar Pharmaceuticals is Now Oversold (AMPH) - Nasdaq
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2021 - ACCESS Newswire
Amphastar Pharmaceuticals Receives FDA Approval for Naloxone Hydrochloride Nasal Spray 4mg - ACCESS Newswire
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2023 - ACCESS Newswire
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2024 - ACCESS Newswire
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2024 - ACCESS Newswire
Amphastar Pharmaceuticals Announces Pricing of Offering of $300.0 Million of Convertible Senior Notes - ACCESS Newswire
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024 - ACCESS Newswire
Amphastar Receives FDA Approval for Vasopressin - ACCESS Newswire
Amphastar Pharmaceuticals to Present at the Barclays 26th Annual Global Healthcare Conference - ACCESS Newswire
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2023 - ACCESS Newswire
Amphastar Announces Additional $50 Million Increase to its Share Buyback Program - ACCESS Newswire
(AMPH) Technical Data - Stock Traders Daily
Amphastar Receives FDA Approval for Ganirelix Acetate Injection - ACCESS Newswire
Possible Bearish Signals With Amphastar Pharmaceuticals Insiders Disposing Stock - Simply Wall St
3.23%
3.94%
大文字化:
|
ボリューム (24 時間):